Aquestive Therapeutics’ (AQST) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock.

AQST has been the topic of a number of other research reports. Raymond James started coverage on shares of Aquestive Therapeutics in a research note on Thursday, March 28th. They set an outperform rating and a $7.00 price objective on the stock. JMP Securities reiterated a market outperform rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Wednesday, June 26th. Piper Sandler started coverage on shares of Aquestive Therapeutics in a research note on Thursday, April 11th. They set an overweight rating and a $10.00 price objective on the stock. Leerink Partnrs upgraded shares of Aquestive Therapeutics to a strong-buy rating in a research note on Friday, May 10th. Finally, SVB Leerink started coverage on shares of Aquestive Therapeutics in a research note on Friday, May 10th. They set an outperform rating and a $8.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Buy and a consensus price target of $7.83.

Aquestive Therapeutics Stock Performance

NASDAQ AQST opened at $3.82 on Friday. Aquestive Therapeutics has a one year low of $1.25 and a one year high of $6.23. The company’s 50 day moving average price is $2.83 and its 200 day moving average price is $3.31. The firm has a market capitalization of $347.77 million, a price-to-earnings ratio of -9.10 and a beta of 2.80.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The company had revenue of $12.05 million for the quarter, compared to analysts’ expectations of $12.22 million. During the same quarter last year, the firm earned $0.11 EPS. Sell-side analysts forecast that Aquestive Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new stake in shares of Aquestive Therapeutics in the second quarter worth $594,000. Virtu Financial LLC boosted its holdings in Aquestive Therapeutics by 219.7% in the first quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock worth $438,000 after purchasing an additional 70,666 shares during the period. Lazard Asset Management LLC boosted its holdings in Aquestive Therapeutics by 115.5% in the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after purchasing an additional 15,601 shares during the period. Vanguard Group Inc. boosted its holdings in Aquestive Therapeutics by 71.7% in the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after purchasing an additional 1,353,518 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Aquestive Therapeutics in the first quarter worth $54,000. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.